Experimental Drug Appears to Slow Down Alzheimer’s Disease

November 30, 2022 by TWN Staff
Experimental Drug Appears to Slow Down Alzheimer’s Disease
Cells in an Alzheimer's-affected brain. (NATIONAL INSTITUTE ON AGING, NIH/AP)

An experimental drug that removes a substance called amyloid — a toxic protein — from the brain appears to slow down Alzheimer’s disease.

The drug, lecanemab, reduced the rate of cognitive decline by 27% in a study of nearly 1,800 people in the early stages of Alzheimer’s, scientists reported at the Clinical Trials on Alzheimer’s Disease meeting in San Francisco, California, on Tuesday.

The study was also published in this week’s edition of The New England Journal of Medicine.

According to Dr. Christopher van Dyck, who directs the Yale Alzheimer’s Disease Research Center and presented an overview of the study at the meeting, patients who got infusions of lecanemab scored about half a point better on a zero-to-18-point scale of mental functioning, a slight but statistically significant difference.



Lecanemab is expected to win preliminary approval from the Food and Drug Administration in January 2023, based on its ability to reduce amyloid. 

But questions about the drug remain. The drug appears to have caused serious side effects like brain swelling and bleeding in more than one in five people who took the medicine, compared to 10% of those who received a placebo. 


Nevertheless, the Alzheimer’s Association called for approval of the medicine, saying it will allow patients more time to live independently and participate in daily life. 

“It could mean many months more of recognizing their spouse, children and grandchildren,” the group said in a statement. “Treatments that deliver tangible benefits to those living with mild cognitive impairment due to Alzheimer’s and early Alzheimer’s dementia are as valuable as treatments that extend the lives of those with other terminal diseases.”

A+
a-

In The News

Health

Voting

Research

January 31, 2023
by TWN Staff
Marburg Vaccine Shows Promising Results in First-In-Human Study

WASHINGTON — An experimental vaccine against Marburg virus, a member of the Ebola virus family that causes death in a... Read More

WASHINGTON — An experimental vaccine against Marburg virus, a member of the Ebola virus family that causes death in a large proportion of infected individuals, proved safe and induced an immune response in a small, first-in-human clinical trial. The findings of the researchers at the National... Read More

January 24, 2023
by Dan McCue
A Probiotic May Control Serious Antibiotic-Resistant Staph Infection

WASHINGTON — A probiotic may be effective in cleansing the body of staph-related super infections, according to a new study... Read More

WASHINGTON — A probiotic may be effective in cleansing the body of staph-related super infections, according to a new study from the National Institute of Allergy and Infectious Diseases. Though they say more research is needed, a press release on the institute’s website stated that their... Read More

January 24, 2023
by Dan McCue
Bacterial Spores Inspire Novel Cancer Drug Delivery System

WASHINGTON — Scientists with the National Cancer Institute’s Center for Cancer Research have come up with a new way to... Read More

WASHINGTON — Scientists with the National Cancer Institute’s Center for Cancer Research have come up with a new way to get life-saving drugs directly into cancer cells, an advance they say will enable more effective treatments for cancer with fewer side effects. The research was originally... Read More

December 21, 2022
by Dan McCue
USDA Developing Tools to Identify COVID in Wild and Domestic Animals

WASHINGTON — The Agriculture Department’s Animal and Plant Inspection Service is developing new tests and tools to identify and track... Read More

WASHINGTON — The Agriculture Department’s Animal and Plant Inspection Service is developing new tests and tools to identify and track the coronavirus and its variants in wild and domestic animals. The initiative, part of a $300 million provision in the American Rescue Plan Act, is being... Read More

December 20, 2022
by Dan McCue
USDA Invests $9.5M to Develop New Bioproducts From Agricultural Commodities

WASHINGTON — The U.S. Department of Agriculture is investing $9.5 million to support the scale-up of sustainable bioproduct manufacturing in... Read More

WASHINGTON — The U.S. Department of Agriculture is investing $9.5 million to support the scale-up of sustainable bioproduct manufacturing in the United States. The three projects being funded through the department’s National Institute of Food and Agriculture included two university-based initiatives and one effort being undertaken... Read More

December 19, 2022
by Dan McCue
$750M Dedicated to Dramatically Reduce Cost of Hydrogen Technologies

WASHINGTON — The Energy Department is making $740 million in bipartisan infrastructure law funding available to dramatically reduce the cost... Read More

WASHINGTON — The Energy Department is making $740 million in bipartisan infrastructure law funding available to dramatically reduce the cost of clean-energy technologies. According to department officials, who announced the funding last week, the infusion of money is crucial to the administration’s effort to accelerate the... Read More

News From The Well
scroll top